FTSE 100 companies BT, Vodafone and Astrazeneca to report earnings this week Tech Key quarterly earning updates from FTSE 100 companies next week, include Vodafone, BT and Astrazeneca.
‘Nobel prize of engineering’ finalist Sunamp to raise Series B as it mulls public offering Industrials An innovative battery firm nominated for the "nobel prize of engineering" is set to raise a Series B funding round in a few months with a future IPO becoming an increasingly "realistic proposition", its boss has said.
Google Deepmind among nominees for ‘Nobel Prize of engineering’ tech AI-powered weather forecasting, innovative heat batteries and the rapid manufacturing scale-up of a Covid vaccine are the three cutting edge technologies nominated for an engineering award dubbed "the Nobel Prize of Engineering".
Oxford Biomedica issues new shares to secure a £17m investment June 18, 2024 Cell and gene therapy company Oxford Biomedica has announced a near £17m investment which will see it issue new shares to the London Stock Exchange.
Astrazeneca swallows up Canada-based Fusion Pharmaceuticals in £1.5bn move June 5, 2024 Astrazeneca has completed its $2bn (£1.5bn) acquisition of Canada-based Fusion Pharmaceuticals, in a deal first announced in March.
‘New era of growth’: FTSE 100 giant Astrazeneca aims to double revenue May 21, 2024 London-listed Astrazeneca reported revenue of $45.8bn in 2023 and growth of 19 per cent to $12.7bn in the first quarter of 2024.
Astrazeneca to build huge new cancer drug plant in Singapore May 20, 2024 Astrazeneca has said it will invest $1.5bn (£1.2bn) to build a manufacturing facility in Singapore to produce antibody drug conjugates (ADCs), a next-generation cancer treatment.
Astrazeneca: London-listed pharma giant heralds successful breast cancer drug April 29, 2024 Astrazeneca has found that Enhertu helped patients live longer without their breast cancer getting worse compared to standard chemotherapy.
Astrazeneca’s revenue surges as pipeline investments pay off April 25, 2024 Pascal Soriot, chief executive officer of AstraZeneca, said: "Astrazeneca had a very strong start in 2024 with substantial total revenue growth of 19 per cent in the first quarter.
Angle agrees deal with Astrazeneca for tech to kill cancer cells April 24, 2024 This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment.